Change in Attitude in Renal Function in Major Beta Thalassemia
Archives of Medical Laboratory Sciences,
Vol. 6 (2020),
20 January 2020
,
Page 1-5 (e24)
https://doi.org/10.22037/amls.v6.33057
Abstract
Thalassemia is a multisystemic disease in the field of hemolysis and chronic anemia caused by the erythropoietic disorder. The severe effects of iron overload from continuous blood transfusion iron chelators side effects, and involvement of multiple organs in thalassemias such as heart failure, liver, and endocrine dysfunction can all affect kidney function. Although there has been much debate about changes in renal function in thalassemia for many years, the presence of hyperfiltration and ultimately, decreased renal function in almost all studies. It seems for the researchers to look beyond kidney function in a thalassemia perspective, because of secretory biomarkers of proximal tubular renal cells that are sensitive to pathologic agents, which may be a good indicator of the courses of treatment and prognosis of patients. Future studies will be sooner or later.
*Corresponding Author: Malihe Najafpour; Email: malihe_najafpour@modares.ac.ir
Please cite this article as: Malaki M, Najafpour M, Talebi M, Azimi A. Change in Attitude in Renal Function in Major Beta Thalassemia. Arch Med Lab Sci. 2020;6:1-5 (e24). https://doi.org/10.22037/amls.v6.33057
- Thalassemia
- Renal complications
- Iron overload
How to Cite
References
Al-Allawi NA, Hassan KM, Sheikha AK, Nerweiy FF, Dawood RS, Jubrael J. beta-Thalassemia Mutations among Transfusion-Dependent Thalassemia Major Patients in Northern Iraq. Molecular biology international. 2010;2010.
Azar keivan A E, Karimi M, Badiyi Z, Aghighi M. Comprehensive package of care for patients with thalassemia. Tehran: Arvij; 2006.
Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Italian journal of pediatrics. 2010;36(1):39.
Mastrangelo F, Lopez T, Rizzelli S, Manisco G, Corlianò C, Alfonso L. Function of the kidney in adult patients with Cooley's disease: a preliminary report. Nephron. 1975;14:229-36.
Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta haematologica. 2010;123:148-52.
Hashemieh M. Early Detection of renal dysfunction in β thalassemia with focus on novel biomarkers. Iranian Journal of Pediatric Hematology and Oncology. 2020;10:57-68.
Demosthenous C, Vlachaki E, Apostolou C, Eleftheriou P, Kotsiafti A, Vetsiou E, et al. Beta-thalassemia: renal complications and mechanisms: a narrative review. Hematology (United Kingdom). 2019;24:426-38.
Lai ME, Spiga A, Vacquer S, Carta MP, Corrias C, Ponticelli C. Renal function in patients with β-thalassaemia major: A long-term follow-up study. Nephrology Dialysis Transplantation. 2012;27:3547-51.
Sadeghi-Bojd S, Hashemi M, Karimi M. Renal tubular function in patients with β-thalassaemia major in Zahedan, southeast Iran. Singapore Medical Journal. 2008;49:410-2.
Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusion-dependent beta thalassaemia. Blood reviews. 2010;24:239-44.
Cianciulli P, Sollecito D, Sorrentino F, Forte L, Gilardi E, Massa A, et al. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney international. 1994;46:467-70.
Naderi M, Sadeghi-Bojd S, Valeshabad AK, Jahantigh A, Alizadeh S, Dorgalaleh A, et al. A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox. Pediatric hematology and oncology. 2013;30:748-54.
Bakr A, Al-Tonbary Y, Osman G, El-Ashry R. Renal complications of beta-thalassemia major in children. American Journal of Blood Research. 2014;4:1-6.
Dimitriadou M, Christoforidis A, Economou M, Teli A, Printza N, Tzimouli V, et al. Fok-I polymorphism of vitamin D receptor gene and the presence of renal dysfunction in patients with β-thalassemia major. Pediatric hematology and oncology. 2011;28:509-16.
Najafpour M, Farshdousti-Hagh M, Movasagpoor-Akbari AA, Feyzi AAHP, Malaki M. Renal damages in patients with major β-thalassemia. Journal of Nephropharmacology. 2020;9:1-5.
Malaki M SSR, Shoaran M, Bagheri Sh. Beta Thalassemia Major: The Effect of Age on Glomerular Filtration Rate. Saudi J Kidney Dis Transpl. 2011;22:963-8.
Basma A. Ali AMM. Frequency of Glomerular Dysfunction in Children with Beta Thalassaemia Major. Sultan Qaboos University Med J. 2014;14:88-94.
Aldudak B, Bayazit AK, Noyan A, Özel A, Anarat A, Sasmaz I, et al. Renal function in pediatric patients with β-thalassemia major. Pediatric nephrology. 2000;15:109-12.
Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, et al. Urine biochemical markers of early renal dysfunction are associated with iron overload in β-thalassaemia. Clinical and Laboratory Haematology. 2003;25:105-9.
Mohkam M, Shamsian BS, Gharib A, Nariman S, Arzanian MT. Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatric nephrology. 2008;23:971-6.
Tantawy AAG, El Bablawy N, Adly AAM, Ebeid FSE. Early predictors of renal dysfunction in Egyptian patients with ß-thalassemia major and intermedia. Mediterranean journal of hematology and infectious diseases. 2014;6(1).
Musallam KM, Taher AT. Mechanisms of renal disease in β-thalassemia. Journal of the American Society of Nephrology. 2012;23:1299-302.
Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. European journal of haematology. 2012;89:187-97.
Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, et al. Early markers of renal dysfunction in patients with sickle cell/β-thalassemia. Kidney international. 2006;69:2037-42.
Harris DC. Tubulointerstitial renal disease. Curr Opin Nephrol Hypertens. 2001;10:303-13.
Şen V, Ece A, Uluca Ü, Söker M, Güneş A, Kaplan I, et al. Urinary early kidney injury molecules in children with beta-thalassemia major. Renal failure. 2015;37:607-13.
Maliheh NAJAF POUR MFH, Ali Akbar MOVASAGPOOR AKBARI , Abbas Ali HOSEIN POOR FEYZI, Majid MALAKI. Genetic Variation Impacts in Patients with Major. 2015;44:722-3.
Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clinica Chimica Acta. 2006;371:1-12.
Najafpour M, Hagh MF, Azimi A, Heydarabad MZ, Balekdari P. Exon 2 Vitamin D Receptor ( Fok-I ) Gene Polymorphism and the Evaluation of its Correlation With Renal Dysfunction in Patients With β -Thalassemia Major in East Azerbaijan Province of Iran. 2020;7:393-7.
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. Aphase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455-62.
Navidi-Shishaone M, Mohhebi S, Nematbakhsh M, Roozbehani S, Talebi A, Pezeshki Z, et al. Co-administration of silymarin and deferoxamine against kidney, liver and heart iron deposition in male iron overload rat model. International Journal of Preventive Medicine. 2014;5:110-6.
Dee CMA, Cheuk DKL, Ha SY, Chiang AKS, Chan GCF. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassemia. British Journal of Haematology. 2014;167:434-6.
- Abstract Viewed: 300 times
- PDF Downloaded: 249 times